UBE3A and non-small cell lung carcinoma: In approximately 20% of non-small cell lung cancer UBE3A levels are decreased, resulting in lower levels of the cyclin-dependent kinase (CDK) inhibitor p16INK4A and a reduction in overall survival [277].